MannKind Corporation heads into its May 8 Q1 earnings call with call buyers firmly in charge — and a stock that has just retraced nearly half of a devastating post-earnings collapse in under six weeks.
The options market is the clearest tell. The put/call ratio has dropped to 0.35, well below its 20-day average of 0.40 and nearly 1.3 standard deviations below that mean — the most call-skewed reading since early spring. That bullish lean arrived alongside an extraordinary price move: MNKD is up 42% over the past month and 29% on the week alone, closing at $3.56 after briefly trading above $5.90 earlier in the quarter. The stock cratered after the February 26 print, falling 6% in a single session and sliding 19% over the following five days. What followed was a recovery that has outpaced almost everything in the small-cap biotech universe.
Short sellers were caught leaning the wrong way. Short interest climbed roughly 22% over the past month as the stock was falling, reaching nearly 30 million shares — about 9.7% of the free float. That positioning has now started to unwind, with SI down around 3% in the most recent session alone. The lending market is not tight: borrow availability is ample and cost to borrow remains negligible at roughly 0.53%, barely changed from levels seen all year. The ORTEX short score has eased from its recent highs, landing around 56 — elevated, but not extreme. This is a short base that grew into a stock's weakness and is now facing a sharp squeeze.
The bull case rests on the durability of Tyvaso DPI royalty income, potential expansion into the IPF and PPF segments, and a growing pediatric pipeline — factors that Wells Fargo found compelling enough to raise its target to $8 (from $7) just ten days ago, even while maintaining its Overweight rating. The bear case is more immediate: Boehringer Ingelheim's Jascayd, the first new IPF therapy in a decade, represents a direct competitive threat to MannKind's most important revenue stream, and patent protection questions add a further overhang. Mizuho trimmed its target to $8 from $10 in mid-April while holding Outperform — a pattern of maintained ratings but shrinking targets that runs across multiple firms. The mean analyst target of $6.94 implies substantial upside from current levels, but the February downgrade from RBC Capital to Sector Perform at $3.50 serves as a reminder of how the Street was positioned just weeks ago, before the recent rally.
The CEO bought 100,000 shares in early March at $2.59, a meaningful signal at the time; the broader institutional picture shows State Street adding nearly 4 million shares as recently as April 30. Those ownership moves now look prescient given the move since. The print tomorrow will test whether the Q1 numbers — particularly any guidance on Tyvaso DPI royalty trajectory and competitive dynamics with Jascayd — justify the market's rapid re-rating, or whether the gap between $3.56 and a $6.94 consensus target conceals a valuation story that the recent rally has already run ahead of.
See the live data behind this article on ORTEX.
Open MNKD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
